How to leverage an endogenous immune defense mechanism: The example of granulocyte colony-stimulating factor

Thomas Hartung, Sonja Von Aulock, Christian Schneider, Eugen Faist

Research output: Contribution to journalArticle

Abstract

Our understanding of host defense has exploded during the past two decades. It is temping to take advantage of this knowledge by considering the modulation and control of these mechanisms as therapeutic options. In intensive care medicine, the aim is usually to block an overwhelming inflammatory response, which represents the "bad" side of the double-edged sword of host defense. The obvious danger of such treatment strategies is that impairing the inflammatory reaction means impairing host defense in patients exposed to infectious agents. The alternative approach, i.e., strengthening or supplementing favorable host defense mechanism, has so far been little explored clinically. Granulocyte colony-stimulating factor, the granulocyte colony-stimulating factor, combines the unique properties of an anti-infectious and an anti-inflammatory factor. This attractive profile has led us to various approaches to exploit these immunomodulatory activities. In a recently terminated, placebo-controlled, randomized study, we investigated if prophylactic treatment with rh granulocyte colony-stimulating factor (Filgrastim), at the time a risk can be anticipated such as before an operation, may offer protection from immunoinflammatory dyshomeostasis and thus lower the incidence of postoperative sepsis. Perioperative rh granulocyte colony-stimulating factor administration, compared with placebo treatment, resulted in the prevention of postoperative monocyte deactivation, conservation of an adequate TH1/TH2 ratio, as well as a considerable alleviation of the acute phase response. In parallel, there was a clear tendency toward lowering the rate of postoperative septic complications under the administration of Filgrastim.

Original languageEnglish (US)
JournalCritical Care Medicine
Volume31
Issue number1 SUPPL.
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Granulocyte Colony-Stimulating Factor
Placebos
Acute-Phase Reaction
Therapeutics
Critical Care
Monocytes
Sepsis
Anti-Inflammatory Agents
Medicine
Incidence
Filgrastim

Keywords

  • Clinical trials
  • Endogenous production
  • Granulocyte colony-stimulating factor
  • Infection
  • Inflammation
  • Perioperative immunomodulation
  • Pleiotropy
  • Redundancy
  • Safety
  • Sepsis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

How to leverage an endogenous immune defense mechanism : The example of granulocyte colony-stimulating factor. / Hartung, Thomas; Von Aulock, Sonja; Schneider, Christian; Faist, Eugen.

In: Critical Care Medicine, Vol. 31, No. 1 SUPPL., 01.01.2003.

Research output: Contribution to journalArticle

Hartung, Thomas ; Von Aulock, Sonja ; Schneider, Christian ; Faist, Eugen. / How to leverage an endogenous immune defense mechanism : The example of granulocyte colony-stimulating factor. In: Critical Care Medicine. 2003 ; Vol. 31, No. 1 SUPPL.
@article{e792a1c868ef4d72885975da35de427b,
title = "How to leverage an endogenous immune defense mechanism: The example of granulocyte colony-stimulating factor",
abstract = "Our understanding of host defense has exploded during the past two decades. It is temping to take advantage of this knowledge by considering the modulation and control of these mechanisms as therapeutic options. In intensive care medicine, the aim is usually to block an overwhelming inflammatory response, which represents the {"}bad{"} side of the double-edged sword of host defense. The obvious danger of such treatment strategies is that impairing the inflammatory reaction means impairing host defense in patients exposed to infectious agents. The alternative approach, i.e., strengthening or supplementing favorable host defense mechanism, has so far been little explored clinically. Granulocyte colony-stimulating factor, the granulocyte colony-stimulating factor, combines the unique properties of an anti-infectious and an anti-inflammatory factor. This attractive profile has led us to various approaches to exploit these immunomodulatory activities. In a recently terminated, placebo-controlled, randomized study, we investigated if prophylactic treatment with rh granulocyte colony-stimulating factor (Filgrastim), at the time a risk can be anticipated such as before an operation, may offer protection from immunoinflammatory dyshomeostasis and thus lower the incidence of postoperative sepsis. Perioperative rh granulocyte colony-stimulating factor administration, compared with placebo treatment, resulted in the prevention of postoperative monocyte deactivation, conservation of an adequate TH1/TH2 ratio, as well as a considerable alleviation of the acute phase response. In parallel, there was a clear tendency toward lowering the rate of postoperative septic complications under the administration of Filgrastim.",
keywords = "Clinical trials, Endogenous production, Granulocyte colony-stimulating factor, Infection, Inflammation, Perioperative immunomodulation, Pleiotropy, Redundancy, Safety, Sepsis",
author = "Thomas Hartung and {Von Aulock}, Sonja and Christian Schneider and Eugen Faist",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "31",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "1 SUPPL.",

}

TY - JOUR

T1 - How to leverage an endogenous immune defense mechanism

T2 - The example of granulocyte colony-stimulating factor

AU - Hartung, Thomas

AU - Von Aulock, Sonja

AU - Schneider, Christian

AU - Faist, Eugen

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Our understanding of host defense has exploded during the past two decades. It is temping to take advantage of this knowledge by considering the modulation and control of these mechanisms as therapeutic options. In intensive care medicine, the aim is usually to block an overwhelming inflammatory response, which represents the "bad" side of the double-edged sword of host defense. The obvious danger of such treatment strategies is that impairing the inflammatory reaction means impairing host defense in patients exposed to infectious agents. The alternative approach, i.e., strengthening or supplementing favorable host defense mechanism, has so far been little explored clinically. Granulocyte colony-stimulating factor, the granulocyte colony-stimulating factor, combines the unique properties of an anti-infectious and an anti-inflammatory factor. This attractive profile has led us to various approaches to exploit these immunomodulatory activities. In a recently terminated, placebo-controlled, randomized study, we investigated if prophylactic treatment with rh granulocyte colony-stimulating factor (Filgrastim), at the time a risk can be anticipated such as before an operation, may offer protection from immunoinflammatory dyshomeostasis and thus lower the incidence of postoperative sepsis. Perioperative rh granulocyte colony-stimulating factor administration, compared with placebo treatment, resulted in the prevention of postoperative monocyte deactivation, conservation of an adequate TH1/TH2 ratio, as well as a considerable alleviation of the acute phase response. In parallel, there was a clear tendency toward lowering the rate of postoperative septic complications under the administration of Filgrastim.

AB - Our understanding of host defense has exploded during the past two decades. It is temping to take advantage of this knowledge by considering the modulation and control of these mechanisms as therapeutic options. In intensive care medicine, the aim is usually to block an overwhelming inflammatory response, which represents the "bad" side of the double-edged sword of host defense. The obvious danger of such treatment strategies is that impairing the inflammatory reaction means impairing host defense in patients exposed to infectious agents. The alternative approach, i.e., strengthening or supplementing favorable host defense mechanism, has so far been little explored clinically. Granulocyte colony-stimulating factor, the granulocyte colony-stimulating factor, combines the unique properties of an anti-infectious and an anti-inflammatory factor. This attractive profile has led us to various approaches to exploit these immunomodulatory activities. In a recently terminated, placebo-controlled, randomized study, we investigated if prophylactic treatment with rh granulocyte colony-stimulating factor (Filgrastim), at the time a risk can be anticipated such as before an operation, may offer protection from immunoinflammatory dyshomeostasis and thus lower the incidence of postoperative sepsis. Perioperative rh granulocyte colony-stimulating factor administration, compared with placebo treatment, resulted in the prevention of postoperative monocyte deactivation, conservation of an adequate TH1/TH2 ratio, as well as a considerable alleviation of the acute phase response. In parallel, there was a clear tendency toward lowering the rate of postoperative septic complications under the administration of Filgrastim.

KW - Clinical trials

KW - Endogenous production

KW - Granulocyte colony-stimulating factor

KW - Infection

KW - Inflammation

KW - Perioperative immunomodulation

KW - Pleiotropy

KW - Redundancy

KW - Safety

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=0037251467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037251467&partnerID=8YFLogxK

M3 - Article

C2 - 12544979

AN - SCOPUS:0037251467

VL - 31

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 1 SUPPL.

ER -